Revangenix is a biopharmaceutical company in California that develops medical treatments. Its filings show it spends money lobbying Congress on health issues, specifically matters tied to biopharmaceutical research and innovation. It has used the firm Forbes-Tate and reported about $200,000 across four filings, most recently on January 18, 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
BARRETT THORNHILL
The latest disclosures for this client.
FORBES-TATE
1TYFORBES-TATE
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
FORBES-TATE
DERRICK M WHITE
FORBES-TATE
KRISTINA DUNKLIN
FORBES-TATE
mr MICHAEL ALEXANDER WILLIAMS
FORBES-TATE
WESLEY RYAN WELCH
FORBES-TATE
FORBES-TATE
Q3FORBES-TATE
Q2FORBES-TATE
Q1